Clinical Trial Update: A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gilteritinib as maintenance therapy after allogeneic transplant in FLT3-ITD acute myeloid leukemia. The study has completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Xospata (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19